Quarterly report pursuant to Section 13 or 15(d)

Summary of Significant Accounting Policies (Details)

v3.22.2.2
Summary of Significant Accounting Policies (Details) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Summary of Significant Accounting Policies (Details) [Line Items]        
Other comprehensive (loss) income $ (1,871,072) $ (530,817) $ (4,507,204) $ 65,018
Foreign currency transaction gains (losses) $ (14,031)   $ (14,151)  
Foreign currency transaction loss   $ (218,834)   (200,264)
Price per share (in Dollars per share) $ 0.67   $ 0.67  
Fair market value $ 26,102,105   $ 26,102,105  
Share issued (in Shares) 39,251,286   39,251,286  
Common stock outstanding (in Shares) 39,246,011   39,246,011  
Voting shares (in Shares)     5,275  
Carrying amount $ 44,974,955   $ 44,974,955  
Total assets 53,200,000   53,200,000  
Total liabilities 8,200,000   8,200,000  
Fair market value $ 18,872,850   18,872,850  
Goodwill, impairment loss     18,872,850
Reduced goodwill     $ 7,608,238  
Unexercised shares (in Shares)     1,085,000  
Pre-Funded Warrants [Member]        
Summary of Significant Accounting Policies (Details) [Line Items]        
Unexercised shares (in Shares)     1,085,000  
CannBioRex Pharmaceuticals Corp. [Member]        
Summary of Significant Accounting Policies (Details) [Line Items]        
Reduced goodwill     $ 11,264,612